asparaginase Erwinia chrysanthemi (Erwinaze)
asparaginase Erwinia chrysanthemi is an FDA-licensed reference biologic from Jazz Pharmaceuticals, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2011
Reference approved
Reference product
Erwinaze asparaginase Erwinia chrysanthemi
Jazz Pharmaceuticals, Inc.
- Approved
- Nov 18, 2011
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for asparaginase Erwinia chrysanthemi, in chronological order.
Reference approval
Approval date of the reference asparaginase Erwinia chrysanthemi product.
14 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for asparaginase Erwinia chrysanthemi (Erwinaze)?
No 351(k) biosimilars or interchangeable biosimilars referencing asparaginase Erwinia chrysanthemi are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.